Exagen Inc. (XGN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Exagen Inc. is a medical technology company focused on the AVISE® brand of testing products for the differential diagnosis and monitoring of rheumatic and autoimmune diseases, primarily systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This report covers the quarterly period ended September 30, 2025. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $17.2M | $12.5M | $49.9M | $42.0M |
| Gross Profit | $10.1M | $7.0M | $29.6M | $24.6M |
| Gross Margin | 58.4% | 55.8% | 59.3% | 58.7% |
| Net Loss | $(7.1M) | $(5.0M) | $(15.3M) | $(11.4M) |
| Loss Per Share (Diluted) | $(0.31) | $(0.28) | $(0.73) | $(0.63) |
| Cash & Equivalents | $35.7M | $22.0M (Dec '24) | N/A | |
| Total Debt (Carrying Value) | $22.9M | $20.2M (Dec '24) | N/A | |
| Operating Cash Flow (9M) | $(10.6M) | $(13.6M) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 37.9% year-over-year (YoY) to $17.2M, driven by a 16% increase in AVISE® CTD test volume and a 9% increase in trailing-twelve-month Average Selling Price (ASP) to $441 per test.
- Margin Expansion: Gross margin improved to 58.4% in Q3 2025 from 55.8% in Q3 2024, attributed to ASP expansion from new biomarkers and improved overhead absorption.
- Debt Restructuring: In April 2025, the company entered a new $75M term loan facility with Perceptive Credit Holdings. The initial $25M tranche was used to fully repay the prior 2017 Term Loan, resulting in a $0.3M loss on extinguishment of debt.
- Equity Raises: The company raised $18.6M net in a public offering in May 2025 and approximately $3.4M net via an At-The-Market (ATM) program in Q3 2025.
- Non-Cash Charges: Net loss was significantly impacted by a $2.7M non-cash charge in Q3 2025 related to the change in fair value of a warrant liability issued in connection with the new debt facility.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing capital resources ($35.7M cash) are sufficient to fund operations for at least the next 12 months. The company has an additional $50M available under the Perceptive facility subject to revenue milestones.
- Product Pipeline: The company launched new SLE, RA, and PAD4 biomarker assays on the AVISE® CTD platform in Q3 2025. Development continues on Lupus Nephritis biomarkers and AI-driven disease activity algorithms.
- Reimbursement Risks: Revenue depends heavily on third-party payor reimbursement. The company faces uncertainty regarding a Local Coverage Determination (LCD) for its AVISE® Lupus test due to a federal regulatory freeze. Commercial payor denials remain a challenge.
- Supply Chain: The company relies on a limited number of suppliers for reagents (97% from two suppliers in Q3 2025). An amended supply agreement includes a $24M minimum purchase commitment through 2029.
- Legal: A qui tam case regarding billing practices was dismissed with prejudice in July 2025, resolving a significant contingency.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the sensitivity of the $6.6M warrant liability to stock price fluctuations and the probability assumptions used for future debt tranches.
- Reimbursement Status: Confirm the current status of the AVISE® Lupus LCD application and the impact of the federal regulatory freeze on Medicare coverage.
- Debt Covenants: Review the specific revenue milestones required to draw the remaining $50M of the Perceptive Term Loan Facility and the consequences of missing them.
- Supplier Concentration: Assess the risk mitigation strategies regarding the high concentration of diagnostic testing supply purchases (95-97% from three suppliers).
- Cash Burn vs. Revenue Growth: Monitor the trajectory of operating cash flow to ensure revenue growth outpaces the increased interest expense and operating costs associated with the new debt and expanded sales force.